|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Several DSPs, mainly MKPs and, unexpectedly, MTMRs, were altered following HER2-modulation in cells and 3 DSPs (DUSP6, CDC25B and MTMR11) were altered in both cells and tumors.
|
20413845 |
2010 |
|
Bipolar Disorder
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Propensity score-based nonparametric test revealing genetic variants underlying bipolar disorder.
|
21254220 |
2011 |
|
Bipolar Disorder
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Propensity score-based nonparametric test revealing genetic variants underlying bipolar disorder.
|
21254220 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, both the protein levels and mRNA levels of cdc25B and Aurora B Kinase, transcriptional targets of FOXM1 were also reduced in tumors treated with anti-FoxM1 siRNA. p27, an indirect target of FOXM1 associated with growth inhibition was further found be increased in tumors treated with FoxM1-siRNA.
|
22203467 |
2011 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In summary, we found that transcriptional repression mediated by IER5 regulates Cdc25B expression levels via the release of NF-YB and p300 in AML-derived ALDH(hi)/CD34(+) cells, resulting in inhibition of AML progenitor cell proliferation through modulation of cell cycle.
|
22132193 |
2011 |
|
Pancreatic Ductal Adenocarcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In the present study, we investigated the transcription status of miRNA-148a (miR-148a) in human pancreatic ductal adenocarcinoma (PDAC) and its role in the regulation of the dual specificity protein phosphatase CDC25B.
|
21709669 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
54 potentially functional polymorphisms in key cell cycle genes (CDK1, CDK2, CDK4, CDK6, CDK7, CCND1, CCND2, CCND3, CCNE1, CCNA1, CCNA2, CCNB1, CCNH, p15, p16, p18, p19, p21, p27, Cdc25A and Cdc25B) were genotyped by using Illumina SNP genotyping platform to evaluate their associations with survival of NSCLC in a clinical cohort of 568 patients.
|
21145615 |
2011 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, we identified CDC25B as a novel miR-148a target which may confer a proliferative advantage in PDAC.
|
21709669 |
2011 |
|
Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To additionally investigate the role of Cdc25B alteration in the development of renal cell carcinoma, Cdc25B siRNA was used to knockdown the expression of Cdc25B.
|
22631674 |
2012 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To additionally investigate the role of Cdc25B alteration in the development of renal cell carcinoma, Cdc25B siRNA was used to knockdown the expression of Cdc25B.
|
22631674 |
2012 |
|
Influenza A
|
0.020 |
Biomarker
|
disease |
BEFREE |
RNAi screening of CDC25B resulted in reduced influenza A virus replication, and a CDC25B small-molecule inhibitor (NSC95397) inhibited influenza A virus replication in a dose-dependent fashion.
|
24109234 |
2013 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Global gene expression analyses showed that patients with AML cell resistance against PI3K-mTOR inhibitors showed increased mRNA expression of the CDC25B gene that encodes the cell cycle regulator Cell Division Cycle 25B.
|
24383842 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The abnormal expression of CDC25B phosphatases detected in a number of tumors implies that their dysregulation is involved in malignant transformation.
|
25680404 |
2015 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Both CDC25B and PED/PEA-15 play a certain role in the carcinogenesis of esophageal cancer, and PED/PEA-15 has a greater influence on postoperative survival time.
|
25775393 |
2015 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of CDC25A and CDC25B showed significant correlation with poor tumour differentiation and tumour invasion (p<0.05).
|
25326518 |
2015 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
The CDC25B protein expression was correlated with differentiation grade and depth of invasion (p<0.05).
|
25775393 |
2015 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
For the first time, we demonstrate that miRNA-211 is a direct negative regulator of CDC25B expression in TNBC cells, alters other related target proteins CCNB1 and FOXM1, and then inhibits breast cancer cells growth, migration, and invasion and lead G2/M arrest.
|
25680404 |
2015 |
|
Esophageal carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Fluorescence quantitative real-time PCR and immunohistochemistry methods were used to analyze the expression of CDC25B, PED/PEA-15 in esophageal carcinoma.
|
25775393 |
2015 |
|
Pancreatic carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We decided to construct a novel oncolytic adenovirus whose replication was driven by the CDC25B promoter for its use in preclinical models of pancreatic cancer.
|
25573380 |
2015 |